Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Protein Effect||no effect|
|Gene Variant Descriptions||TP53 over exp indicates an over expression of the Tp53 protein. However, the mechanism causing the over expression is unspecified.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 over exp||ovarian cancer||predicted - sensitive||HLA-A2 p53:264-272 vaccine||Phase I||Actionable||In a Phase I trial, the HLA-A2 p53:264-272 vaccine demonstrated safety and preliminary efficacy in patients with TP53 overexpressing ovarian cancer, resulting in a progression-free survival of 5.5 months and an overall survival of 40.4 months (PMID: 21927947).||21927947|
|Molecular Profile||Protein Effect||Treatment Approaches|
|TP53 over exp||no effect|